Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Reply to Comment on "Malfitano, A.M. et al. Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer" Cancers 2019, 11, 1532.

Malfitano AM, Di Somma S, Prevete N, Portella G.

Cancers (Basel). 2020 Jan 23;12(2). pii: E281. doi: 10.3390/cancers12020281.

2.

G-Quadruplex Binders Induce Immunogenic Cell Death Markers in Aggressive Breast Cancer Cells.

Di Somma S, Amato J, Iaccarino N, Pagano B, Randazzo A, Portella G, Malfitano AM.

Cancers (Basel). 2019 Nov 15;11(11). pii: E1797. doi: 10.3390/cancers11111797.

3.

Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer.

Malfitano AM, Somma SD, Prevete N, Portella G.

Cancers (Basel). 2019 Oct 10;11(10). pii: E1532. doi: 10.3390/cancers11101532. Review.

4.

The Oncolytic Virus dl922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth.

Di Somma S, Iannuzzi CA, Passaro C, Forte IM, Iannone R, Gigantino V, Indovina P, Botti G, Giordano A, Formisano P, Portella G, Malfitano AM, Pentimalli F.

Front Oncol. 2019 Jul 12;9:564. doi: 10.3389/fonc.2019.00564. eCollection 2019.

5.

Platinum(II) O,S Complexes Inhibit the Aggregation of Amyloid Model Systems.

Florio D, Malfitano AM, Di Somma S, Mügge C, Weigand W, Ferraro G, Iacobucci I, Monti M, Morelli G, Merlino A, Marasco D.

Int J Mol Sci. 2019 Feb 14;20(4). pii: E829. doi: 10.3390/ijms20040829.

6.

Structural insights into amyloid structures of the C-terminal region of nucleophosmin 1 in type A mutation of acute myeloid leukemia.

Di Natale C, La Manna S, Malfitano AM, Di Somma S, Florio D, Scognamiglio PL, Novellino E, Netti PA, Marasco D.

Biochim Biophys Acta Proteins Proteom. 2019 Jun;1867(6):637-644. doi: 10.1016/j.bbapap.2019.01.010. Epub 2019 Jan 30.

PMID:
30710643
7.

Nucleophosmin-1 regions associated with acute myeloid leukemia interact differently with lipid membranes.

De Santis A, La Manna S, Krauss IR, Malfitano AM, Novellino E, Federici L, De Cola A, Di Matteo A, D'Errico G, Marasco D.

Biochim Biophys Acta Gen Subj. 2018 Apr;1862(4):967-978. doi: 10.1016/j.bbagen.2018.01.005. Epub 2018 Jan 10. No abstract available.

PMID:
29330024
8.

Immuno-Modulatory and Anti-Inflammatory Effects of Dihydrogracilin A, a Terpene Derived from the Marine Sponge Dendrilla membranosa.

Ciaglia E, Malfitano AM, Laezza C, Fontana A, Nuzzo G, Cutignano A, Abate M, Pelin M, Sosa S, Bifulco M, Gazzerro P.

Int J Mol Sci. 2017 Jul 28;18(8). pii: E1643. doi: 10.3390/ijms18081643.

9.

Characterization of linear mimetic peptides of Interleukin-22 from dissection of protein interfaces.

La Manna S, Scognamiglio PL, Di Natale C, Leone M, Mercurio FA, Malfitano AM, Cianfarani F, Madonna S, Caravella S, Albanesi C, Novellino E, Marasco D.

Biochimie. 2017 Jul;138:106-115. doi: 10.1016/j.biochi.2017.05.002. Epub 2017 May 4.

PMID:
28479106
10.

Cannabidiol: State of the art and new challenges for therapeutic applications.

Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M.

Pharmacol Ther. 2017 Jul;175:133-150. doi: 10.1016/j.pharmthera.2017.02.041. Epub 2017 Feb 22. Review.

PMID:
28232276
11.

Immunomodulatory properties of 1,2-dihydro-4-hydroxy-2-oxo-1,8-naphthyridine-3-carboxamide derivative VL15.

Malfitano AM, Laezza C, Bertini S, Marasco D, Tuccinardi T, Bifulco M, Manera C.

Biochimie. 2017 Apr;135:173-180. doi: 10.1016/j.biochi.2017.02.009. Epub 2017 Feb 20.

PMID:
28219703
12.
13.

Endocannabinoid System in Neurological Disorders.

Ranieri R, Laezza C, Bifulco M, Marasco D, Malfitano AM.

Recent Pat CNS Drug Discov. 2016;10(2):90-112. Review.

PMID:
27364363
14.

Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders.

Ranieri R, Marasco D, Bifulco M, Malfitano AM.

Recent Pat CNS Drug Discov. 2016 Jun 19. [Epub ahead of print]

PMID:
27334611
15.

Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response.

Ranieri R, Laezza C, Bifulco M, Marasco D, Malfitano AM.

Recent Pat CNS Drug Discov. 2016;10(2):178-203. Review.

PMID:
27334610
16.

Molecular signaling involving intrinsically disordered proteins in prostate cancer.

Russo A, Manna SL, Novellino E, Malfitano AM, Marasco D.

Asian J Androl. 2016 Sep-Oct;18(5):673-81. doi: 10.4103/1008-682X.181817. Review.

17.

Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders.

Ranieri R, Marasco D, Bifulco M, Malfitano AM.

Recent Pat CNS Drug Discov. 2016;10(2):157-177. Review.

PMID:
27184693
18.

Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis.

Malfitano AM, Laezza C, Pisanti S, Manera C, Bifulco M.

Recent Pat CNS Drug Discov. 2016;10(2):113-121.

PMID:
27097974
19.

Breast adiponcosis: a call for further research.

Bifulco M, Malfitano AM.

Endocrine. 2017 Jan;55(1):326-327. doi: 10.1007/s12020-015-0839-8. Epub 2016 Jan 4. No abstract available.

PMID:
26725314
20.

p53 regulates the mevalonate pathway in human glioblastoma multiforme.

Laezza C, D'Alessandro A, Di Croce L, Picardi P, Ciaglia E, Pisanti S, Malfitano AM, Comegna M, Faraonio R, Gazzerro P, Bifulco M.

Cell Death Dis. 2015 Oct 15;6:e1909. doi: 10.1038/cddis.2015.279.

21.

Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells.

Ciaglia E, Torelli G, Pisanti S, Picardi P, D'Alessandro A, Laezza C, Malfitano AM, Fiore D, Pagano Zottola AC, Proto MC, Catapano G, Gazzerro P, Bifulco M.

Oncotarget. 2015 Jun 20;6(17):15464-81.

22.

New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.

Manera C, Malfitano AM, Parkkari T, Lucchesi V, Carpi S, Fogli S, Bertini S, Laezza C, Ligresti A, Saccomanni G, Savinainen JR, Ciaglia E, Pisanti S, Gazzerro P, Di Marzo V, Nieri P, Macchia M, Bifulco M.

Eur J Med Chem. 2015 Jun 5;97:10-8. doi: 10.1016/j.ejmech.2015.04.034. Epub 2015 Apr 24.

PMID:
25935384
23.

Comment on "the negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia.".

Bifulco M, Malfitano AM.

Haematologica. 2015 Mar;100(3):e118-9. doi: 10.3324/haematol.2014.122168. No abstract available.

24.

N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice.

Ciaglia E, Pisanti S, Picardi P, Laezza C, Sosa S, Tubaro A, Vitale M, Gazzerro P, Malfitano AM, Bifulco M.

Pharmacol Res. 2014 Nov;89:1-10. doi: 10.1016/j.phrs.2014.07.003. Epub 2014 Jul 22.

PMID:
25063359
25.

Statins in neurological disorders: an overview and update.

Malfitano AM, Marasco G, Proto MC, Laezza C, Gazzerro P, Bifulco M.

Pharmacol Res. 2014 Oct;88:74-83. doi: 10.1016/j.phrs.2014.06.007. Epub 2014 Jun 19. Review.

PMID:
24954580
26.

What we know and do not know about the cannabinoid receptor 2 (CB2).

Malfitano AM, Basu S, Maresz K, Bifulco M, Dittel BN.

Semin Immunol. 2014 Oct;26(5):369-79. doi: 10.1016/j.smim.2014.04.002. Epub 2014 May 28. Review.

27.

1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor.

Lucchesi V, Parkkari T, Savinainen JR, Malfitano AM, Allarà M, Bertini S, Castelli F, Del Carlo S, Laezza C, Ligresti A, Saccomanni G, Bifulco M, Di Marzo V, Macchia M, Manera C.

Eur J Med Chem. 2014 Mar 3;74:524-32. doi: 10.1016/j.ejmech.2013.10.070. Epub 2014 Jan 21.

PMID:
24518874
28.

Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation.

Pisanti S, Picardi P, Ciaglia E, Margarucci L, Ronca R, Giacomini A, Malfitano AM, Casapullo A, Laezza C, Gazzerro P, Bifulco M.

FASEB J. 2014 Mar;28(3):1132-44. doi: 10.1096/fj.13-238238. Epub 2013 Nov 21.

PMID:
24265487
29.

N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A.

Bifulco M, D'Alessandro A, Paladino S, Malfitano AM, Notarnicola M, Caruso MG, Laezza C.

FEBS J. 2013 Dec;280(23):6223-32. doi: 10.1111/febs.12544. Epub 2013 Nov 18.

30.

Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives.

Malfitano AM, Laezza C, Saccomanni G, Tuccinardi T, Manera C, Martinelli A, Ciaglia E, Pisanti S, Vitale M, Gazzerro P, Bifulco M.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1077-86. doi: 10.1007/s11481-013-9494-0. Epub 2013 Oct 1.

PMID:
24081326
31.

N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation.

Ciaglia E, Pisanti S, Picardi P, Laezza C, Malfitano AM, D'Alessandro A, Gazzerro P, Vitale M, Carbone E, Bifulco M.

J Leukoc Biol. 2013 Dec;94(6):1207-19. doi: 10.1189/jlb.0413190. Epub 2013 Jul 11.

PMID:
23847096
32.

Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis.

Malfitano AM, Laezza C, D'Alessandro A, Procaccini C, Saccomanni G, Tuccinardi T, Manera C, Macchia M, Matarese G, Gazzerro P, Bifulco M.

PLoS One. 2013 May 1;8(5):e62511. doi: 10.1371/journal.pone.0062511. Print 2013.

33.

Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells.

Laezza C, d'Alessandro A, Malfitano AM, Bifulco M.

Eur J Cancer. 2013 May;49(8):2066-7. doi: 10.1016/j.ejca.2013.01.026. Epub 2013 Feb 21. No abstract available.

PMID:
23434151
34.

Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.

Manera C, Saccomanni G, Malfitano AM, Bertini S, Castelli F, Laezza C, Ligresti A, Lucchesi V, Tuccinardi T, Rizzolio F, Bifulco M, Di Marzo V, Giordano A, Macchia M, Martinelli A.

Eur J Med Chem. 2012 Jun;52:284-94. doi: 10.1016/j.ejmech.2012.03.031. Epub 2012 Mar 24.

PMID:
22483967
35.

The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.

Malfitano AM, Laezza C, Galgani M, Matarese G, D'Alessandro A, Gazzerro P, Bifulco M.

Pharmacol Res. 2012 Mar;65(3):365-71. doi: 10.1016/j.phrs.2011.11.008. Epub 2011 Nov 22.

PMID:
22123497
36.

Pharmacological actions of statins: a critical appraisal in the management of cancer.

Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M.

Pharmacol Rev. 2012 Jan;64(1):102-46. doi: 10.1124/pr.111.004994. Epub 2011 Nov 21. Review.

PMID:
22106090
37.

Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth.

Proto MC, Gazzerro P, Di Croce L, Santoro A, Malfitano AM, Pisanti S, Laezza C, Bifulco M.

J Cell Physiol. 2012 Jan;227(1):250-8. doi: 10.1002/jcp.22727.

PMID:
21412772
38.

Update on the endocannabinoid system as an anticancer target.

Malfitano AM, Ciaglia E, Gangemi G, Gazzerro P, Laezza C, Bifulco M.

Expert Opin Ther Targets. 2011 Mar;15(3):297-308. doi: 10.1517/14728222.2011.553606. Epub 2011 Jan 19. Review.

PMID:
21244344
39.

Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice.

Malfitano AM, Sosa S, Laezza C, De Bortoli M, Tubaro A, Bifulco M.

Br J Pharmacol. 2011 Jan;162(1):84-93. doi: 10.1111/j.1476-5381.2010.01047.x. Erratum in: Br J Pharmacol. 2019 Jan;176(1):128.

40.

Involvement of Akt/NF-κB pathway in N6-isopentenyladenosine-induced apoptosis in human breast cancer cells.

Laezza C, Malfitano AM, Di Matola T, Ricchi P, Bifulco M.

Mol Carcinog. 2010 Oct;49(10):892-901. doi: 10.1002/mc.20666.

PMID:
20672320
41.

Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells.

Laezza C, Malfitano AM, Proto MC, Esposito I, Gazzerro P, Formisano P, Pisanti S, Santoro A, Caruso MG, Bifulco M.

Endocr Relat Cancer. 2010 May 18;17(2):495-503. doi: 10.1677/ERC-10-0009. Print 2010 Jun.

PMID:
20304978
42.

Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin.

Gazzerro P, Malfitano AM, Proto MC, Santoro A, Pisanti S, Caruso MG, Notarnicola M, Messa C, Laezza C, Misso G, Caraglia M, Bifulco M.

Oncol Rep. 2010 Jan;23(1):171-5.

PMID:
19956878
43.

Cannabinoid receptor CB1 antagonists state of the art and challenges.

Bifulco M, Santoro A, Laezza C, Malfitano AM.

Vitam Horm. 2009;81:159-89. doi: 10.1016/S0083-6729(09)81007-8. Review.

PMID:
19647112
44.

Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon.

Santoro A, Pisanti S, Grimaldi C, Izzo AA, Borrelli F, Proto MC, Malfitano AM, Gazzerro P, Laezza C, Bifulco M.

Int J Cancer. 2009 Sep 1;125(5):996-1003. doi: 10.1002/ijc.24483.

45.

Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.

Pisanti S, Malfitano AM, Grimaldi C, Santoro A, Gazzerro P, Laezza C, Bifulco M.

Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):117-31. doi: 10.1016/j.beem.2009.02.001. Review.

PMID:
19285265
46.

Cannabinoids in the management of spasticity associated with multiple sclerosis.

Malfitano AM, Proto MC, Bifulco M.

Neuropsychiatr Dis Treat. 2008 Oct;4(5):847-53.

47.

N6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1.

Laezza C, Caruso MG, Gentile T, Notarnicola M, Malfitano AM, Di Matola T, Messa C, Gazzerro P, Bifulco M.

Int J Cancer. 2009 Mar 15;124(6):1322-9. doi: 10.1002/ijc.24056. Erratum in: Int J Cancer. 2014 Nov 15;135(10):E11.

48.

The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway.

Laezza C, Pisanti S, Malfitano AM, Bifulco M.

Endocr Relat Cancer. 2008 Dec;15(4):965-74. doi: 10.1677/ERC-08-0030. Epub 2008 Aug 1.

PMID:
18676619
49.

Endocannabinoids in endocrine and related tumours.

Bifulco M, Malfitano AM, Pisanti S, Laezza C.

Endocr Relat Cancer. 2008 Jun;15(2):391-408. doi: 10.1677/ERC-07-0258. Review.

PMID:
18508995
50.

Potential therapeutic role of statins in neurological disorders.

Bifulco M, Malfitano AM, Marasco G.

Expert Rev Neurother. 2008 May;8(5):827-37. doi: 10.1586/14737175.8.5.827. Review.

PMID:
18457539

Supplemental Content

Loading ...
Support Center